|
1
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venkitaraman AR: Cancer susceptibility and
the functions of BRCA1 and BRCA2. Cell. 108:171–182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos
MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, et al: BRCA1
inhibition of estrogen receptor signaling in transfected cells.
Science. 284:1354–1356. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Narod SA and Foulkes WD: BRCA1 and BRCA2:
1994 and beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Y: BRCA1, hormone, and tissue-specific
tumor suppression. Int J Biol Sci. 5:20–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caestecker KW and Van de Walle GR: The
role of BRCA1 in DNA double-strand repair: Past and present. Exp
Cell Res. 319:575–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huszno J, Budryk M, Kołosza Z and Nowara
E: The influence of BRCA1/BRCA2 mutations on toxicity related to
chemotherapy and radiotherapy in early breast cancer patients.
Oncology. 85:278–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang
C, Liu X, Wang X, Li H, Kang C, et al: MiR-124 governs glioma
growth and angiogenesis and enhances chemosensitivity by targeting
R-Ras and N-Ras. Neuro Oncol. 16:1341–1353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stupp R, Mason WP, Van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups, ; National Cancer Institute of
Canada Clinical Trials Group, : Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim LPLN, Lau NC, Garrett-Engele P,
Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson
JM: Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature. 433:769–773. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai NP, Lin YL and Wei LN: MicroRNA
mir-346 targets the 5′-untranslated region of receptor-interacting
protein 140 (RIP140) mRNA and up-regulates its protein expression.
Biochem J. 424:411–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang HW, Wang F, Wei Q, Zhao YF, Liu M, Li
X and Tang H: miR-20a promotes migration and invasion by regulating
TNKS2 in human cervical cancer cells. FEBS Lett. 586:897–904. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Díaz-López A, Moreno-Bueno G and Cano A:
Role of microRNA in epithelial to mesenchymal transition and
metastasis and clinical perspectives. Cancer Manag Res. 6:205–216.
2014.PubMed/NCBI
|
|
15
|
Zhao L, Bode AM, Cao Y and Dong Z:
Regulatory mechanisms and clinical perspectives of miRNA in tumor
radiosensitivity. Carcinogenesis. 33:2220–2227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Zhang D, Chen C, Ruan Z, Li Y and
Huang Y: MicroRNA-212 displays tumor-promoting properties in
non-small cell lung cancer cells and targets the hedgehog pathway
receptor PTCH1. Mol Biol Cell. 23:1423–1434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scapoli L, Palmieri A, Lo Muzio L,
Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and
Carinci F: MicroRNA expression profiling of oral carcinoma
identifies new markers of tumor progression. Int J Immunopathol
Pharmacol. 23:1229–1234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang X, Zeng J, Wang L, Fang M, Wang Q,
Zhao M, Xu X, Liu Z, Li W, Liu S, et al: Histone demethylase
retinoblastoma binding protein 2 is overexpressed in hepatocellular
carcinoma and negatively regulated by hsa-miR-212. PLoS One.
8:e697842013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiping Z, Ming F, Lixiang W, Xiuming L,
Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C, et al:
MicroRNA-212 inhibits proliferation of gastric cancer by directly
repressing retinoblastoma binding protein 2. J Cell Biochem.
114:2666–2672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu L, Wang F, Xu XF, Mo WH, Xia YJ, Wan R,
Wang XP and Guo CY: Down-regulation of miR-212 expression by DNA
hypermethylation in human gastric cancer cells. Med Oncol. 28 Suppl
1:S189–S196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng X, Wu J, Pan C, Wang H, Ying X, Zhou
Y, Yu H, Zuo Y, Pan Z, Liu RY, et al: Genetic and epigenetic
down-regulation of microRNA-212 promotes colorectal tumor
metastasis via dysregulation of MnSOD. Gastroenterology.
145:426–436.e1-e6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA Profiling of Prostate Cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gandellini P, Rancati T, Valdagni R and
Zaffaroni N: miRNAs in tumor radiation response: Bystanders or
participants? Trends Mol Med. 20:529–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakaguchi M, Hisamori S, Oshima N, Sato F,
Shimono Y and Sakai Y: miR-137 regulates the tumorigenicity of
colon cancer stem cells through the inhibition of DCLK1. Mol Cancer
Res. 14:354–362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang X, Chen X, Chen L, Ma Y, Zhou L, Qi
Q, Liu Y, Zhang S, Luo J and Zhou X: Upregulation of the
miR-212/132 cluster suppresses proliferation of human lung cancer
cells. Oncol Rep. 33:705–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou C, Smith JL and Liu J: Role of BRCA1
in cellular resistance to paclitaxel and ionizing radiation in an
ovarian cancer cell line carrying a defective BRCA1. Oncogene.
22:2396–2404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kan C and Zhang J: BRCA1 mutation: A
predictive marker for radiation therapy? Int J Radiat Oncol Biol
Phys. 93:281–293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saha J and Davis AJ: Unsolved mystery: The
role of BRCA1 in DNA end-joining. J Radiat Res (Tokyo). 57 Suppl
1:i18–i24. 2016. View Article : Google Scholar
|
|
29
|
Bencokova Z, Pauron L, Devic C, Joubert A,
Gastaldo J, Massart C, Balosso J and Foray N: Molecular and
cellular response of the most extensively used rodent glioma models
to radiation and/or cisplatin. J Neurooncol. 86:13–21. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boukerroucha M, Josse C, Segers K,
El-Guendi S, Frères P, Jerusalem G and Bours V: BRCA1 germline
mutation and glioblastoma development: Report of cases. BMC Cancer.
15:1812015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chai KM, Wang CY, Liaw HJ, Fang KM, Yang
CS and Tzeng SF: Downregulation of BRCA1-BRCA2-containing complex
subunit 3 sensitizes glioma cells to temozolomide. Oncotarget.
5:10901–10915. 2014. View Article : Google Scholar : PubMed/NCBI
|
